N-acetylglucosaminyltransferase III Antagonizes the Effect of N-acetylglucosaminyltransferase V on Alpha3beta1 Integrin-mediated Cell Migration
Overview
Authors
Affiliations
N-acetylglucosaminyltransferase V (GnT-V) catalyzes the addition of beta1,6-GlcNAc branching of N-glycans, which contributes to metastasis. N-acetylglucosaminyltransferase III (GnT-III) catalyzes the formation of a bisecting GlcNAc structure in N-glycans, resulting in the suppression of metastasis. It has long been hypothesized that the suppression of GnT-V product formation by the action of GnT-III would also exist in vivo, which will consequently lead to the inhibition of biological functions of GnT-V. To test this, we draw a comparison among MKN45 cells, which were transfected with GnT-III, GnT-V, or both, respectively. We found that alpha3beta1 integrin-mediated cell migration on laminin 5 was greatly enhanced in the case of GnT-V transfectant. This enhanced cell migration was significantly blocked after the introduction of GnT-III. Consistently, an increase in bisected GlcNAc but a decrease in beta1,6-GlcNAc-branched N-glycans on integrin alpha3 subunit was observed in the double transfectants of GnT-III and GnT-V. Conversely, GnT-III knockdown resulted in increased migration on laminin 5, concomitant with an increase in beta1,6-GlcNAc-branched N-glycans on the alpha3 subunit in CHP134 cells, a human neuroblastoma cell line. Therefore, in this study, the priority of GnT-III for the modification of the alpha3 subunit may be an explanation for why GnT-III inhibits GnT-V-induced cell migration. Taken together, our results demonstrate for the first time that GnT-III and GnT-V can competitively modify the same target glycoprotein and furthermore positively or negatively regulate its biological functions.
Implication of protein post translational modifications in gastric cancer.
Song H, Zhang M, Guo C, Guo X, Ma Y, Ma Y Front Cell Dev Biol. 2025; 13:1523958.
PMID: 39968176 PMC: 11833226. DOI: 10.3389/fcell.2025.1523958.
Macke A, Pachikov A, Divita T, Morris M, LaGrange C, Holzapfel M Mol Cancer Res. 2023; 21(9):958-974.
PMID: 37314749 PMC: 10527559. DOI: 10.1158/1541-7786.MCR-23-0108.
Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy.
Yue J, Huang R, Lan Z, Xiao B, Luo Z Biomark Res. 2023; 11(1):54.
PMID: 37231524 PMC: 10214721. DOI: 10.1186/s40364-023-00491-8.
Yale A, Kim E, Gutierrez B, Hanamoto J, Lav N, Nourse J Stem Cell Reports. 2023; 18(6):1340-1354.
PMID: 37172586 PMC: 10277816. DOI: 10.1016/j.stemcr.2023.04.007.
Huang Z, Lai P, Cocker A, Haslam S, Dell A, Brady H Biochem Soc Trans. 2023; 51(2):639-653.
PMID: 36929183 PMC: 10212547. DOI: 10.1042/BST20221406.